A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) — Ampyra  

Non Arteritic Ischemic Optic Neuropathy Clinical Trial

Official title: Dalfampridine Treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

Status Completed

Clinical Trial Summary

Determine whether dalfampridine (Ampyra) can improve visual function in patients who have had nonarteritic ischemic optic neuropathy (NAION) with stable visual impairment.

Clinical Trial Description

The aim of this study is to determine whether dalfampridine can improve visual function in patients who have had nonarteritic ischemic optic neuropathy (NAION) with stable visual impairment.

The objective of this double masked crossover study is to determine whether visual function can be improved in numerous parameters. This includes high contrast visual acuity, low contrast visual acuity, visual field, visual quality of life (VFQ-39), electrophysiology, multi focal electro retinography (mERG), visual evoked potential (VEP), and structure, spectral domain optical coherence tomography (OCT).

Based on the promising results of the use of dalfampridine in Multiple Sclerosis (MS) and in stroke, we hypothesize that the patients with chronic stable deficits after nonarteritic ischemic optic neuropathy (NAION) will have improved visual function with the administration of dalfampridine. ;

Related Conditions & MeSH terms

• Ischemia
• Non Arteritic Ischemic Optic Neuropathy
• Optic Nerve Diseases
• Optic Neuropathy, Ischemic

• NCT number: NCT01975324
• Study type: Interventional
• Source: Neuro-Ophthalmologic Associates, PC
• Status: Completed
• Phase: Phase 4
• Start date: July 2013
• Completion date: December 2015